(Reuters) – The U.S. Food & Drug Administration plans to approve Pfizer Inc and BioNTech SE’s request to store their COVID-19 vaccine at standard freezer temperatures instead of in ultra-cold conditions, the New York Times reported on Tuesday.
The FDA is expected to announce new guidance to the providers as early as Tuesday, modifying documents related to the emergency use authorization that was previously granted for the vaccine, the NYT report said, citing people familiar with the matter
Last week, the companies said they asked the U.S. health regulator to relax requirements for their COVID-19 vaccine to be stored at ultra-low temperatures, potentially allowing it to be kept in pharmacy freezers.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Shailesh Kuber)
